Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
The 7 Best Biotech Stocks to Buy
01:45pm, Tuesday, 20'th Sep 2022
I've written before about how biotech is the biggest technology trend of our kids' generation. Naturally, that means many people are looking for the best biotech stocks to buy.
Why Is Ionis Pharmaceuticals (IONS) Down 5.8% Since Last Earnings Report?
12:47pm, Thursday, 08'th Sep 2022
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
Ionis to present at upcoming investor conferences
07:05am, Tuesday, 30'th Aug 2022
CARLSBAD, Calif. , Aug. 30, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 20
Ionis: 2 Drug Advancements With Potential Firsts
05:54pm, Monday, 29'th Aug 2022
A PDUFA date of January 25, 2023 has been established for possible approval of tofersen for the treatment of patients with SOD1-ALS. An NDA filing of eplontersen for the treatment of patients with ATT
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
12:14pm, Wednesday, 10'th Aug 2022 Zacks Investment Research
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates. Stock moves down in response to the results.
Ionis (IONS) Q2 Earnings & Sales Miss Estimates, Stock Down
09:47am, Wednesday, 10'th Aug 2022
Ionis (IONS) incurs a wider-than-expected loss in Q2. Its sales also miss estimates.
Ionis Pharmaceuticals, Inc. (IONS) CEO Brett Monia on Q2 2022 Results - Earnings Call Transcript
03:39pm, Tuesday, 09'th Aug 2022
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2022 Earnings Conference Call August 9, 2022 11:30 AM ET Company Participants Brett Monia - Chief Executive Officer Beth Hougen - Chief Financial Officer
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates
12:15pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharmaceuticals (IONS) Reports Q2 Loss, Lags Revenue Estimates
09:47am, Tuesday, 09'th Aug 2022
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of -21.31% and 9.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Ionis Pharma Extends Breakout; Biotech Restates Guide Despite Quarterly Miss
08:58am, Tuesday, 09'th Aug 2022
Ionis Pharmaceuticals broadly missed second-quarter expectations Tuesday but reiterated its 2022 outlook and IONS stock inched up. The post Ionis Pharma Extends Breakout; Biotech Restates Guide Despit
The Zacks Analyst Blog Highlights Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade
01:22pm, Monday, 08'th Aug 2022 Zacks Investment Research
Take-Two Interactive Software, Ionis Pharmaceuticals, Celsius Holdings, Grocery Outlet Holding and Lemonade are part of Zacks top Analyst Blog.
Why Ionis Pharmaceuticals (IONS) Might Surprise This Earnings Season
12:58pm, Monday, 08'th Aug 2022 Zacks Investment Research
Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Why Ionis Pharmaceuticals (IONS) Might Surprise This Earnings Season
10:33am, Monday, 08'th Aug 2022
Ionis Pharmaceuticals (IONS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ironwood (IRWD) Q2 Earnings Miss, Keeps 2022 Sales Guidance
03:45pm, Friday, 05'th Aug 2022 Zacks Investment Research
Ironwood (IRWD) miss earnings and revenue estimates in the second quarter. Stock declines.
5 Stocks to Buy Ahead of Earnings Results Next Week
11:02am, Friday, 05'th Aug 2022 Zacks Investment Research
Five companies are slated to beat earnings estimates next week. These are: TTWO, IONS, CELH, LMND and GO.
